Treatments affecting the activity of cancer-associated fibroblasts (CAF) or tumor-associated macrophages (TAM) (e.g. monoclonal antibodies such as anti-CD47 or anti-CD40) redirect T-cells to these nominal target cells which appear to be associated with improved anti-tumor responses in a clinical setting (31–36). The gene discussed is CD47; the disease is neoplasm.